sinc
discoveri
clear
dendrit
cell
dc
stood
immun
cell
pack
morpholog
distinct
immun
cell
type
gift
unparallel
capac
take
process
present
self
foreign
antigen
cell
dc
critic
intermediari
innat
adapt
immun
system
stimul
regul
shape
immun
toler
disguis
ralph
steinmann
discov
cell
award
nobel
prize
medicin
discoveri
dc
chang
medicin
dendrit
cell
human
mice
repres
popul
least
four
differ
subtyp
distinct
phenotyp
function
characterist
subset
plasmacytoid
dc
pdc
two
subset
convent
dc
inflammatori
dc
latter
repres
monocytederiv
subset
appear
inflammatori
respons
tabl
recent
addit
type
human
blood
dc
monocyt
progenitor
reveal
use
singl
cell
rnasequenc
group
prof
nir
hacohen
identifi
pdc
next
cdc
progenitorderiv
two
type
one
also
deriv
dc
furthermor
found
dc
subset
deriv
monocyt
axl
subset
futur
research
unravel
possibl
murin
repres
human
axl
dc
subset
also
langerhan
cell
consid
import
dc
subset
vaccin
local
epidermi
hladr
howev
recent
evid
suggest
relat
macrophag
anoth
antigenpres
cell
apc
type
potenti
antitumor
activ
differ
dc
subset
endow
distinct
function
pdc
special
sens
viral
infect
end
pdc
use
tolllik
receptor
stimul
interferon
gene
sting
sens
nucleic
acid
ssrna
dsdna
cytosol
dna
respect
trigger
receptor
result
product
high
level
type
interferon
ifn
key
function
requir
product
andor
type
ifn
activ
cytotox
lymphocyt
ctl
via
crosspresent
antigen
link
herewith
stimul
helper
respons
select
express
enabl
sens
dsrna
similar
pdc
express
sens
dsdna
express
explain
abil
produc
type
ifn
inflammatori
dc
also
abl
produc
stimul
th
cell
cell
crosspresent
depend
activ
instig
specif
immun
respons
inflammatori
dc
equip
wide
rang
tlr
allow
becom
activ
upon
contact
variou
stimuli
like
polyi
c
lp
dc
subset
cooper
wide
rang
immun
respons
mechan
rel
conserv
across
mammalian
speci
knowledg
human
dc
subset
counterpart
mice
enabl
use
murin
model
studi
potenti
dc
cancer
vaccin
gener
antitumor
vaccin
compris
one
tumorassoci
antigen
taa
adjuv
avoid
induct
taaspecif
toler
due
exquisit
capac
dc
crosspres
stimul
antitumor
immun
appli
natur
adjuv
cancer
vaccin
studi
therefor
autolog
dc
gener
load
ex
vivo
one
taa
possibl
addit
dc
activ
stimuli
subsequ
transfer
back
patient
induc
taaspecif
ctl
respons
exemplifi
sipuleucelt
trade
name
proveng
dendreon
first
autolog
dcvaccin
approv
fda
specif
approv
treatment
metastat
hormonerefractori
prostat
cancer
vaccin
consist
autolog
dc
load
fusion
protein
consist
prostat
acid
phosphatas
pap
granulocyt
macrophagecoloni
stimul
factor
gmcsf
clinic
trial
dcbase
vaccin
autolog
monocytederiv
dc
modc
use
howev
modc
recapitul
natur
divers
dc
rather
mimic
inflammatori
dc
awar
modc
might
ideal
suit
vaccin
purpos
togeth
overal
limit
efficaci
clinic
trial
stimul
research
use
cdc
pdc
clinic
compar
clinic
trial
challeng
task
signific
differ
type
antigen
use
ii
type
system
use
deliv
antigen
iii
protocol
use
activ
dc
iv
rout
dc
administr
v
heterogen
inclus
criteria
patient
select
bia
nonetheless
dare
state
clinic
data
hint
better
outcom
upon
cdc
pdcbase
cancer
vaccin
compar
clinic
data
obtain
modcbas
vaccin
could
suggest
need
cooper
multipl
apc
subset
induc
effect
antitumor
immun
optim
prime
antivir
cell
investig
respons
fundament
similar
antitumor
immun
respons
accumul
pdc
site
cell
activ
led
local
recruit
via
chemokin
secret
cell
cellmedi
reorgan
local
dc
network
allow
cooper
pdc
enhanc
matur
subsequ
crosspresent
antigen
find
suggest
stimul
one
dc
subset
like
optim
ctl
stimul
togeth
fact
vaccin
patientspecif
ex
vivo
engin
dc
costli
cumbersom
method
research
move
situ
engin
dc
allow
target
natur
dc
subset
moreov
impli
assent
cooper
subset
optim
ctl
activ
situ
roughli
distinguish
four
type
situ
dcdirect
vaccin
nake
protein
nake
nucleic
acid
viral
vector
nanoparticl
gener
nake
protein
nucleic
acidbas
vaccin
rel
easi
gener
howev
need
codeliv
adjuv
achiev
robust
antitumor
immun
contrast
nanoparticl
viral
vector
repres
immunogen
vaccin
viral
vector
explain
fact
taa
truli
produc
viral
vector
upon
infect
next
deliveri
intrins
immunogen
viral
protein
trigger
type
ifn
respons
vivo
vaccin
mice
viral
vector
compar
peptid
dna
dcvaccin
strongest
tumorspecif
immun
respons
elicit
viral
vector
despit
knowledg
viral
vector
taken
lead
clinic
antitumor
vaccin
trial
therefor
review
use
advantag
well
shortcom
viral
vector
vaccin
highlight
potenti
particular
focu
clinic
applic
furthermor
touch
upon
preclin
data
viral
vector
type
clinic
test
yet
poxvirus
envelop
dsdna
virus
linear
genom
infect
mammalian
cell
major
advantag
poxvirusderiv
vector
abil
accept
larg
insert
foreign
dna
deliv
larg
transgen
target
cell
includ
dc
tabl
sinc
viral
replic
transcript
occur
sole
cytoplasm
host
cell
risk
insert
mutagenesi
preclud
attenu
viral
system
via
delet
certain
pathogen
gene
safeti
poxvirusderiv
vector
enhanc
disabl
gener
infect
viral
particl
complet
life
cycl
exemplifi
recombin
vaccinia
viru
base
attenu
wyeth
strain
anoth
interest
asset
fact
poxvirusderiv
vector
rel
easi
produc
hightit
stabil
current
speci
divid
genera
describ
famili
human
vertebr
arthropod
serv
natur
host
vaccinia
viru
prototyp
poxviru
administ
roughli
one
billion
peopl
profoundli
success
smallpox
erad
program
latter
pave
way
clinic
evalu
anticanc
vaccin
accordingli
extens
evalu
therapeut
vaccin
live
recombin
vaccinia
viru
encod
taa
carcinoembryon
antigen
cea
prostat
specif
antigen
psa
start
year
ago
exampl
recombin
vaccinia
viru
express
cea
psa
rvcea
rvpsa
administ
advanc
carcinoma
metastat
androgen
independ
prostat
cancer
patient
respect
induc
elev
level
antitaa
antibodi
next
taaspecif
ctl
capabl
lyse
taaexpress
tumor
cell
vitro
despit
immunolog
occurr
lack
clinic
respons
tumor
regress
patient
observ
may
explain
inadequ
clonal
expans
andor
cytotox
vivo
next
low
antibodi
titer
low
affin
importantli
though
long
plaqu
form
unit
pfu
inject
signific
treatmentrel
toxic
observ
apart
inject
site
reaction
erythema
pustul
format
patient
previous
vaccin
smallpox
result
mark
contrast
preclin
evalu
taaexpress
recombin
viral
vaccin
show
signific
anticanc
activ
anim
model
suggest
reason
margin
clinic
effect
intrins
toler
taa
human
immunosuppress
effect
tumor
microenviron
furthermor
epitop
domin
viral
antigen
taa
could
deriv
immunolog
focu
cancer
cell
toward
viral
vector
phenomenon
reinforc
observ
rvcea
psa
could
administ
twice
result
measur
immun
respons
third
inject
viral
vectorneutr
antibodi
complet
diminish
cellular
andor
humor
antitaa
effect
search
altern
less
compunct
preexist
immun
led
evalu
two
avipoxvir
strain
name
canarypox
alvac
fowlpox
furthermor
attenu
strain
vaccinia
name
modifi
vaccinia
ankara
mva
gener
via
repeat
passag
time
chicken
embryo
fibroblast
interestingli
alvac
fowlpox
mva
infect
replic
mammalian
cell
increas
overal
patient
safeti
ensur
taaexpress
week
infect
cell
death
induc
within
viral
infect
cell
sinc
clinic
respons
replicationdefici
poxvir
vector
also
margin
repeat
vaccin
still
suffer
viral
epitop
domin
suggest
use
primeboost
regimen
increas
therapeut
outcom
regimen
gener
consist
least
two
differ
consecut
administ
poxvir
strain
express
taa
attempt
determin
primeboost
regimen
use
small
random
trial
compar
rvcea
initi
prime
vaccin
three
alvaccea
inject
vaaa
vs
three
vaccin
alvaccea
follow
one
rvcea
aaav
ifn
product
cell
respons
cea
peptid
much
higher
vaaa
arm
aaav
arm
furthermor
correl
strike
differ
overal
surviv
five
vs
zero
patient
nine
respect
studi
suggest
optim
usag
poxvir
vaccin
done
prime
recombin
vaccinia
follow
booster
vaccin
recombin
nonrepl
vaccin
andor
vector
one
appli
poxvir
vaccin
clinic
trial
repres
psaencod
prostvac
often
deliv
via
primeboost
regimen
consist
recombin
vaccinia
follow
fowlpox
viru
inject
outlin
first
chapter
review
dc
main
driver
immun
repres
lead
target
vaccin
sinc
sever
dc
subtyp
differ
matur
polar
state
coexist
situ
induct
polar
antitumor
ctl
respons
requir
proper
stimul
howev
direct
inject
taaencod
viral
vaccin
result
infect
apc
nonapc
latter
case
taa
express
via
mhci
infect
cell
via
mhcii
apc
infect
nonapc
releas
taa
upon
cell
death
via
secret
viral
vaccin
directli
infect
dc
process
taa
abundantli
present
via
mhci
mhcii
togeth
appropri
costimulatori
molecul
initi
cytotox
ctl
respons
especi
mhcii
target
signal
invari
chain
ii
andor
crosspres
stimul
calreticulin
nonhemolyt
part
listeria
monocytogen
virul
factor
listeriolysin
codeliv
inject
mice
bear
human
papilloma
viru
hpv
immort
tumor
vaccinia
encod
fuse
listeriolysin
result
enhanc
uptak
present
via
mhci
mhci
mhcii
respect
tumor
appear
regress
increas
amount
secret
ctl
within
spleen
note
vaccin
mhci
direct
listeriolysin
result
high
intratumor
ctl
infiltr
well
due
abid
rel
weak
clinic
respons
rate
viral
vaccin
pimp
costimulatori
signal
skew
climat
multigen
construct
gener
includ
taa
well
one
costimulatori
gene
could
aid
stimul
dc
situ
proper
stimul
taaspecif
ctl
build
promis
preclin
data
inject
intramuscularli
patient
advanc
unresect
ceaexpress
malign
viru
could
induc
ceaspecif
peripher
blood
cell
proport
patient
patient
demonstr
transient
diseas
stabil
diseas
regress
interestingli
preclin
efficaci
mva
mainli
attribut
cell
polyclon
antibodi
weak
cell
respons
induc
therefor
addit
stimulatori
immun
checkpoint
like
inclus
mgitrlfus
protein
test
preclin
enhanc
ctl
respons
robust
tumor
regress
improv
overal
surviv
report
use
viral
vector
encod
mgitrlfus
protein
link
stimul
strong
antitumor
ctlrespons
deplet
regulatori
cell
treg
current
observ
point
favor
ad
sever
costimulatori
molecul
one
vaccin
mvabas
cancer
vaccin
target
antigen
test
phase
ii
trial
renal
cell
carcinoma
patient
metastat
combin
though
object
clinic
respons
observ
form
complet
partial
tumor
regress
improv
overal
surviv
demonstr
antivaccin
antibodi
cell
ctl
respons
report
importantli
patient
ctl
show
longer
surviv
compar
overal
popul
also
sever
clinicalgrad
poxvir
vaccin
approach
prostvac
alvac
regularli
test
inclus
triad
immun
enhanc
costimulatori
molecul
name
intercellular
adhes
leukocyt
functionassoci
antigen
collect
design
tricom
formula
use
vaccin
mice
superior
taaspecif
respons
describ
compar
construct
contain
one
two
molecul
vaccinia
boost
regim
encod
two
taa
cea
treatment
pancreat
cancer
term
panvac
also
evalu
alongsid
tricom
phase
ii
result
promis
increas
median
surviv
patient
pretrial
life
expect
month
howev
phase
iii
trial
demonstr
surviv
benefit
encouragingli
two
differ
studi
enrol
patient
metastat
ovarian
breast
cancer
show
taaspecif
immun
administr
poxviralbas
vaccin
immun
result
stabl
breast
cancer
diseas
tumor
shrinkag
even
one
complet
respons
signific
drop
serum
interestingli
poxvirus
also
inject
intratumor
bring
taa
costimulatori
signal
close
proxim
melanoma
lesion
inject
recombin
vaccinia
viru
express
tricom
clinic
respons
shown
patient
furthermor
vacciniabas
vaccin
encod
psa
tricom
inject
intratumor
patient
local
recurr
prostat
cancer
higher
number
tumorinfiltr
cell
could
demonstr
furthermor
local
treg
function
reduc
patient
stabl
improv
serum
psa
level
final
alvac
also
test
intratumor
deliv
adjuv
combin
alvac
encod
human
alvac
encod
human
patient
surgic
incur
melanoma
fourteen
patient
receiv
intratumor
inject
day
unexpectedli
tumor
inject
show
higher
intratumor
level
immunosuppress
cytokin
like
vegf
decreas
intratumor
level
proinflammatori
cytokin
compar
tumor
inject
salin
tumor
regress
observ
patient
develop
neutral
antibodi
alvac
suggest
proinflammatori
intratumor
strategi
also
lead
induct
neg
feedback
mechan
aggrav
immunosuppress
tumor
climat
addit
costimulatori
molecul
adjuv
growth
factor
gmcsf
ad
increas
target
dc
load
approach
shown
induc
local
system
tumor
immun
effect
clinic
respons
exemplifi
random
studi
prostvac
gmcsf
empti
viral
vector
salin
inject
primari
object
improv
progressionfre
surviv
reach
howev
increas
median
overal
surviv
compar
control
subject
report
vs
month
p
also
alvaccea
compar
combin
adjuv
gmcsf
diseas
stabil
seen
compar
patient
receiv
combin
next
costimulatori
cytokin
growth
factor
trial
poxvir
vaccin
evalu
combinatori
potenti
anticanc
treatment
target
therapi
chemo
radiotherapi
larg
random
phase
iii
trial
involv
patient
metastat
renal
cancer
conduct
use
combin
firstlin
treatment
receptor
tyrosin
kinas
inhibitor
sunitinib
overal
surviv
benefit
seen
vaccin
arm
howev
analysi
larger
trial
reveal
signific
correl
magnitud
antibodi
respons
improv
patient
surviv
contrast
phase
ii
trial
combin
firstlin
chemotherapi
cisplatin
plu
gemcitabin
advanc
nonsmal
cell
lung
cancer
nsclc
demonstr
signific
month
increas
median
surviv
recent
shown
random
phase
ii
studi
nsclc
patient
combin
sever
chemotherapi
regimen
led
respons
correl
improv
surviv
treatment
furthermor
respons
associ
ctl
respons
nonvaccin
taa
thu
evidenc
epitop
spread
final
recombin
vaccinia
viru
encod
fusion
protein
evalu
heat
shock
protein
encod
dna
imiquimod
led
potent
antigendirect
antibodi
cytotox
respons
phase
iii
clinic
trial
patient
pre
malign
cervic
lesion
sinc
arriv
antagonist
checkpoint
inhibitor
therapi
also
combinatori
potenti
poxvir
vaccin
test
metastat
castrationresist
prostat
cancer
dose
limit
effect
observ
chemotherapi
patient
psa
declin
baselin
despit
grow
use
poxvir
vector
antitumor
vaccin
candid
cancer
encod
divers
rang
taa
cea
psa
nyeso
epstein
barr
viru
nuclear
latent
membran
antigen
melanoma
antigen
recogn
tyrosinas
innat
stimulatori
properti
remain
poorli
character
interestingli
innat
immun
profil
elicit
alvac
mva
new
york
vaccinia
viru
nyvac
compar
vivo
rhesu
monkey
vitro
human
peripher
blood
mononuclear
cell
pbmc
appear
distinct
alvac
elicit
higher
induct
proinflammatori
ifnrel
antivir
cytokin
chemokin
day
follow
immun
addit
alvac
stimulatori
phenotyp
influenc
sever
pbmc
subset
cell
monocyt
macrophag
pdc
furthermor
stimulatori
phenotyp
observ
follow
prime
alvac
mva
nyvac
reduc
poxvir
vector
use
boost
interestingli
hanwel
et
al
compar
taaexpress
immunogen
deliv
alvac
mva
express
chicken
embryo
fibroblast
equal
vector
system
alvacderiv
much
faster
degrad
compar
mvaderiv
furthermor
transgen
mous
model
use
measur
ctlrespons
upon
vaccin
shown
vector
encod
elicit
low
immeasur
respons
irrespect
viru
strain
use
contrast
mvavector
encod
elicit
significantli
higher
respons
alvacvector
encod
reflect
vitro
taa
express
stabil
studi
confirm
complex
possibl
immunolog
outcom
depend
immunogen
vector
well
transgen
encod
vivo
stabil
transgen
express
order
vaccin
primeboost
regimen
addit
studi
requir
evalu
correl
differ
innat
signatur
subsequ
adapt
immun
respons
protect
efficaci
adenovirus
nonenvelop
dsdna
virus
effici
deliv
dna
divid
quiescent
cell
like
dc
furthermor
readili
produc
high
titer
ifuml
concentr
ifuml
earli
cancer
vaccin
studi
use
replicationincompet
variant
delet
region
serotyp
encod
rang
taa
howev
human
show
preexist
immun
virus
result
lifelong
exposur
wild
type
viru
especi
common
serotyp
hamper
therapeut
efficaci
induct
neutral
antivir
antibodi
andor
ctlmediat
immun
moreov
entail
risk
toxic
upon
system
adenovir
vector
administr
search
safer
adenovir
vector
third
gener
high
capac
hcadv
strip
viral
code
sequenc
engin
consequ
hcadv
less
immunogen
furthermor
hcadc
larger
packag
capac
kb
adenovir
vector
trial
relat
dc
activ
situ
trial
use
taaencod
vaccin
encod
proinflammatori
factor
type
type
ii
ifn
et
cetera
costimulatori
molecul
preclin
test
variou
adenovirusbas
antitumor
vaccin
demonstr
induct
protect
humor
cellular
immun
well
erad
establish
tumor
mice
differ
rout
administr
compar
intraven
intraderm
deliveri
appear
efficaci
antitumor
immun
though
preclin
anim
model
often
respond
well
vaccin
variabl
vaccin
respons
elicit
cancer
patient
littl
therapeut
benefit
phase
studi
metastat
melanoma
show
encod
n
n
safe
fail
induc
immunolog
clinic
efficaci
remark
one
patient
receiv
vaccin
complet
respons
observ
could
attribut
vaccin
one
way
decreas
vector
neutral
antibodi
deliv
heterolog
primeboost
patient
receiv
nake
dna
encod
prostatespecif
membran
antigen
psma
show
sign
success
immun
inocul
pfu
psmaencod
viral
vector
follow
psma
plasmid
boost
hand
nsclc
patient
receiv
sequenti
dna
adenovir
vaccin
code
lung
tumor
antigen
intramuscularli
result
seroreact
one
patient
preexist
immun
adenovir
serotyp
might
explanatori
variabl
efficaci
support
studi
design
circumv
antibodymedi
neutral
ex
vivo
approach
ie
infect
dc
use
cellular
vaccin
one
studi
advanc
melanoma
patient
receiv
dc
transduc
adenovir
vaccin
encod
one
patient
experienc
complet
respons
three
develop
postvaccin
vitiligo
latter
signifi
gener
antigenspecif
immun
even
abl
break
toler
selfantigen
anoth
phase
iii
studi
metastat
melanoma
patient
receiv
three
intraderm
inject
adenovir
transduc
dc
vaccinationinduc
cell
respons
found
evalu
patient
respect
evid
epitop
spread
obtain
two
patient
impli
elicit
cell
show
strong
tumor
reactiv
patient
receiv
three
vaccin
one
consid
tumor
free
four
durabl
stabl
diseas
one
remain
diseasefre
becom
elig
surgic
resect
posit
outcom
limit
highli
immunogen
melanoma
phase
trial
also
perform
nsclc
patient
show
success
individu
case
patient
receiv
multipl
vaccin
dc
transduc
encod
adenovir
vector
patient
demonstr
partial
tumor
regress
stabl
diseas
recent
multigenet
modifi
dc
vaccin
gener
base
adenoviru
deliv
two
differ
taa
survivin
agonist
flagellin
dc
matur
rna
interfer
moieti
silenc
intracellular
immun
checkpoint
molecul
vaccin
found
safe
induc
complet
remiss
rate
phase
trial
acut
myeloid
leukemia
patient
conclus
adenovir
vaccin
mainli
evalu
ex
vivo
modif
dc
sinc
preexist
immun
hamper
repeat
inject
vivo
whether
situ
target
dc
nextgener
adenovir
vector
lead
tumor
regress
remain
evalu
member
retrovirida
character
ssrna
genom
revers
transcrib
provir
dna
cytoplasm
infect
host
cell
subsequ
provir
dna
insert
host
cell
genom
lead
perman
gene
transfer
asset
make
retrovirus
ideal
blue
print
develop
gene
therapi
vector
perman
modifi
target
cell
choic
two
genera
within
retrovirida
famili
commonli
appli
name
lentivirus
member
retrovirida
replic
divid
cell
lentivirus
uniqu
replic
nondivid
cell
howev
lentivir
vector
lv
effici
transduc
dc
revers
transcript
process
requir
cellular
deoxynucleosid
triphosph
extrem
low
dc
interestingli
addit
lentivir
accessori
protein
vpx
lv
abl
enhanc
dcspecif
infect
counter
low
dntp
level
furthermor
lv
transduct
dc
affect
immunophenotyp
viabil
matur
capabl
lack
preexist
immun
allow
repeat
inject
howev
first
clinic
trial
perform
vector
success
treat
xlink
sever
combin
immunodefici
result
develop
leukemia
four
nine
children
due
oncoretrovirusmedi
activ
oncogen
unfortun
event
creat
major
setback
translat
vector
deriv
retrovirida
famili
clinic
applic
though
lv
deriv
differ
genu
lower
propens
integr
potenti
danger
region
within
human
genom
studi
instig
optim
safer
lv
system
engin
envelop
provir
andor
packag
protein
addit
safeti
featur
compris
mutat
lv
integras
impair
provir
integr
host
genom
although
featur
reduc
risk
insert
mutagenesi
nonintegr
lv
express
less
stabl
remain
episom
lose
transgen
target
cell
replic
adenovir
vector
despit
ampl
preclin
evid
lv
repres
safe
potent
anticanc
vaccin
clinic
use
purpos
remain
low
field
adopt
transfer
ex
vivo
transduc
chimer
antigen
receptor
cell
cart
cell
lv
taken
promin
place
cancer
therapi
clinic
trial
regist
today
activ
vaccinationrel
clinic
trial
involv
subcutan
deliv
integrasedefici
lv
encod
addit
directli
target
dc
vivo
pseudotyp
modifi
sindbi
viru
envelop
protein
dcsign
term
preclin
murin
model
show
could
inject
three
time
recal
peaklevel
ctl
furthermor
biodistribut
appear
limit
site
inject
drain
lymph
node
therapeut
efficaci
tumor
bear
mice
current
evalu
phase
ii
clinic
trial
advanc
relaps
metastat
solid
tumor
express
melanoma
sarcoma
ovarian
cancer
small
cell
lung
cancer
vaccin
either
use
singl
agent
combin
cancer
drug
drug
includ
antiprogram
death
therapi
pembrolizumab
far
first
femal
patient
metastat
recurr
synovi
sarcoma
induc
robust
cell
respons
three
inject
subsequ
diseas
regress
year
furthermor
intraderm
togeth
intramuscular
deliveri
studi
combin
product
term
vaccin
regimen
treatment
sarcoma
compris
recombin
protein
trigger
glucopyranosyl
lipid
adjuv
stabl
emuls
glase
potenti
synergist
immunostimulatori
antineoplast
activ
far
vaccin
regimen
well
toler
gener
strong
specif
immun
respons
sarcoma
patient
signific
growth
arrest
overal
surviv
rate
gener
result
stronger
broader
integr
respons
alon
underpin
potenti
heterolog
primeboost
regimen
final
fulli
enrol
openlabel
random
phase
ii
studi
current
evalu
safeti
efficaci
combin
therapi
atezolizumab
patient
advanc
sarcoma
far
patient
receiv
combin
experienc
greater
clinic
benefit
robust
immun
improv
overal
surviv
compar
atezolizumab
alon
togavirida
compris
alphavirus
small
envelop
virus
transfer
selfrepl
ssrna
genom
advantag
alphavirus
therapeut
vaccin
highlevel
express
encod
protein
due
genom
replic
next
lack
preexist
immun
addit
hightit
viru
product
achiev
less
day
high
cost
strong
prefer
express
neuron
cell
made
alphavirus
particularli
use
neurobiolog
studi
gener
alphavirusbas
vector
replicationdefici
requir
helper
vector
packag
recombin
particl
semliki
forest
viru
sfv
venezuelan
equin
enceph
vee
sindbi
viru
engin
effici
replicationdefici
compet
vector
moreov
variant
sindbi
viru
preclin
explor
differenti
abil
target
activ
dc
vitro
vivo
importantli
human
mous
dc
differenti
infect
select
variant
suggest
differ
receptor
express
human
murin
dc
despit
result
sfv
vee
test
clinic
potenti
engin
dc
situ
sfv
insect
alphaviru
abl
infect
divid
nondivid
cell
replicationincompet
sfvbase
vector
encod
hpv
deriv
antigen
evalu
preclin
vector
current
test
phase
clinic
trial
treatment
pre
malign
cervic
lesion
furthermor
replicationdefect
sfvvector
evalu
encod
adjuv
encapsul
cation
liposom
encapsul
approach
tend
passiv
target
tumor
enabl
repeat
administr
without
gener
antivir
immun
safeti
administ
sfvbase
vector
intraven
shown
phase
clinic
studi
melanoma
renal
cell
carcinoma
patient
addit
describ
phase
iii
protocol
treatment
glioblastoma
multiform
vaccin
infus
intratumor
secondli
viruslik
replicon
gener
attenu
strain
vee
potenti
antineoplast
activ
selfamplifi
replicon
evalu
phase
clinic
trial
safeti
efficaci
deliv
term
specif
patient
breast
cancer
evalu
alon
combin
therapi
trastuzumab
importantli
earli
clinic
data
report
doselimit
toxic
support
safeti
vaccin
addit
two
trial
viruslik
replicon
encod
cea
term
regist
treatment
colon
andor
colorect
breast
lung
pancreat
cancer
immun
respons
gener
colorect
cancer
patient
compar
stage
iii
iv
patient
latter
show
trend
longer
surviv
contrast
antibodi
cell
respons
tend
higher
stage
iii
patient
possibl
reflect
less
immunosuppress
milieu
latter
strong
cytotox
effect
alphavirusbas
vector
host
cell
hold
drawback
use
anticanc
vaccin
moieti
contrast
featur
highli
appreci
oncolyt
vector
reflect
amount
ongo
studi
oncolyt
alphavirusbas
vector
rhabdovirida
envelop
bulletshap
rhabdo
refer
rod
virion
encapsul
ssrna
cancer
therapi
famili
mainli
known
oncolyt
viru
member
deriv
among
other
vesicular
stomat
viru
maraba
viru
framework
antitumor
vaccin
famili
clinic
repres
one
vaccin
term
inactiv
rabi
vaccin
combin
polyi
c
advanc
solid
malign
grant
orphan
drug
design
fda
treatment
hepatocellular
carcinoma
pancreat
cancer
respect
vaccin
shown
reactiv
suppress
tumor
microenviron
stimul
cell
dc
macrophag
b
cell
ctl
nk
cell
downregul
treg
current
also
phase
trial
treatment
liver
breast
cancer
upon
intramuscular
administr
ongo
paramyxovirida
repres
measl
virusderiv
vector
envelop
ssrna
virus
mainli
test
oncolyt
therapeut
confusingli
two
clinic
trial
evalu
therapeut
vaccin
potenti
oncolyt
ceaencod
vector
deriv
edmonston
measl
strain
mvcea
importantli
cea
use
taa
facilit
vivo
monitor
viral
gene
express
replic
first
studi
start
particip
treatment
ovarian
epitheli
cancer
primari
periton
cancer
intraperiton
deliveri
mvcea
well
toler
result
stabl
diseas
patient
trial
initi
assess
safeti
toxic
intratumor
administr
mvcea
treatment
recurr
glioblastoma
multiform
trial
suspend
result
disclos
far
gener
consensu
publish
pre
clinic
studi
virusbas
vaccin
potenti
safe
efficaci
nevertheless
rais
overal
surviv
rate
finetun
clinic
test
immin
aav
small
replicationdefect
nonenvelop
ssdna
parvovirus
replic
insid
cell
presenc
helper
viru
adenoviru
howev
aav
genom
establish
latenc
persist
episom
absenc
helper
viru
rare
case
even
integr
host
genom
particularli
specif
region
chromosom
aav
abl
infect
divid
nondivid
cell
make
attract
deliveri
transgen
dc
moreov
sustain
longterm
gene
express
low
immunogen
characterist
good
safeti
profil
make
appeal
candid
immunotherapi
aav
vector
contain
gene
use
infect
mous
dc
effici
gene
transfer
dc
activ
observ
upregul
next
cell
stimul
similarli
aav
use
infect
human
dc
cytomegaloviru
antigen
psa
lactadherin
membraneassoci
selfglycoprotein
express
breast
cancer
cell
analog
observ
mous
dc
effici
activ
prime
antigenspecif
ctl
upon
infect
observ
furthermor
aavderiv
vector
encod
protein
use
immun
balbc
mice
intramuscularli
strong
antibodi
titer
observ
next
accumul
apc
macrophag
dc
addit
ad
benefit
covaccin
adenoviru
encod
murin
gmcsf
shown
also
addit
minim
promotor
aav
express
cassett
improv
infect
dc
abil
stimul
ctl
even
though
aav
less
immunogen
adenovir
vector
antibodi
neutral
due
previou
exposur
patient
multipl
aav
serotyp
remain
common
limit
success
gene
therapi
repeat
vaccin
numer
aav
serotyp
identifi
far
variabl
tropism
depend
rout
administr
therefor
obviou
approach
overcom
neutral
antibodi
specif
aav
serotyp
use
differ
serotyp
natur
occur
aav
variant
enhanc
outcom
aav
immun
ration
design
capsid
perform
sitedirect
mutagenesi
surfaceexpos
serin
threonin
residu
capsidoptim
aav
serotyp
show
increas
transduct
effici
bonemarrow
deriv
dc
addit
intramuscular
inject
prostat
tumor
bear
mice
result
papspecif
ctl
induct
tumor
growth
suppress
studi
set
stage
clinic
applic
capsidoptim
aav
clinic
studi
employ
aav
far
aim
use
ex
vivo
aavmodifi
dc
expand
ceaspecif
ctl
present
blood
patient
grade
iv
gastric
cancer
use
cell
adopt
transfer
envelop
coronavir
vector
carri
kb
autonom
replic
ssrna
genom
offer
advantag
safe
sinc
creat
dna
intermedi
upon
infect
furthermor
abl
exploit
divers
rang
surfac
molecul
infect
target
cell
recogn
dcspecif
ctype
lectin
dcsign
endow
abil
target
dc
vitro
vivo
group
volker
thiel
evidenc
biosaf
coronavirusbas
vector
encod
human
melana
without
gmcsf
addit
report
singl
intraven
immun
pfu
result
prophylact
therapeut
immun
respons
metastat
melanoma
furthermor
also
show
human
dc
transduc
melanarecombin
human
coronaviru
effici
activ
tumorspecif
ctl
group
also
demonstr
vector
encod
exhibit
higher
capac
induc
dc
matur
compar
vector
deliv
former
effici
induc
tumorspecif
ctl
expand
epitop
repertoir
result
therapeut
tumor
immun
natur
dc
tropism
combin
rel
low
dose
need
hold
high
potenti
futur
clinic
evalu
howev
coronovirida
believ
caus
signific
amount
common
cold
human
adult
risk
vaccinationlimit
preexist
immun
issu
need
investig
papillomavirus
small
nonenvelop
circular
dsdna
virus
wide
accept
chronic
infect
certain
hpv
genotyp
form
major
etiolog
factor
cervic
cancer
prophylact
vaccin
hpvderiv
capsid
protein
embed
viruslik
particl
profoundli
exploit
therapeut
vaccin
oncogen
antigen
repres
ideal
target
essenti
induct
mainten
cellular
transform
today
sever
therapeut
vaccin
treatment
hpv
cervic
malign
investig
howev
primeboost
adenoviru
type
vector
perform
cervicovagin
model
antigen
high
system
cell
respons
fail
induc
intraepitheli
ctl
necessari
protect
local
challeng
observ
suggest
epitheli
tropism
hpv
endow
interest
featur
use
therapeut
vaccin
major
advantag
hpv
viral
vector
system
hpv
pseudovector
capac
packag
plasmid
kb
length
complet
devoid
viral
sequenc
upon
hpv
intravagin
primeboost
differ
hpv
serotyp
durabl
cervicovagin
antigenspecif
ctl
respons
induc
promot
local
prolifer
retent
prime
ctl
envelop
famili
baculovirida
preclin
evalu
develop
anticanc
vaccin
famili
form
except
sens
normal
infect
insect
larval
stage
henc
sinc
proven
use
biopesticid
field
agricultur
furthermor
baculovirusmedi
express
recombin
heterolog
protein
cultur
insect
mammalian
cell
also
repres
wide
use
robust
protein
product
method
vaccin
tumorspecif
immunoglobin
id
consid
valuabl
approach
treatment
lymphoma
patient
method
improv
immunogen
explor
lead
id
product
via
baculovirusinfect
cell
due
addit
termin
mannos
residu
typic
recombin
protein
express
insect
cell
id
protein
enhanc
immunostimulatori
properti
moreov
id
show
higher
bind
activ
capac
human
dc
next
higher
elicit
tumorspecif
ctl
erad
preestablish
murin
lymphoma
recent
baculovirus
consid
use
gene
therapi
well
infect
though
replic
mammalian
cell
show
low
cytotox
abl
carri
larg
foreign
gene
kb
span
genom
baculoviru
shown
effici
transduc
activ
dc
ex
vivo
upregul
costimulatori
molecul
mhc
type
ifn
proinflammatori
cytokin
moreov
dc
gener
robust
antitumor
immun
tumor
bear
mice
intraderm
inject
wild
type
baculoviru
adjuv
togeth
tumor
cell
lysat
also
shown
antitumor
efficaci
sever
murin
cancer
model
final
ceaspecif
cell
respons
observ
upon
intramuscular
inject
cea
encod
baculovirusderiv
vector
although
report
preexist
antibaculoviru
immun
vector
could
highli
immunogen
rapidli
inactiv
human
serum
complement
upon
system
deliveri
preclin
studi
warrant
though
dctransduc
capac
larg
gene
insert
capac
biosafeti
profil
repres
promis
featur
futur
develop
potent
anticanc
vaccin
taaspecif
ctl
respons
frequent
induc
upon
vaccin
taaencod
viral
vector
respons
poorli
translat
prolong
surviv
benefit
cancer
patient
lack
overal
clinic
efficaci
assign
fact
patient
receiv
immunosuppress
chemo
therapeut
regimen
prior
vaccin
preexist
induc
vectorneutr
antibodi
lack
elig
taa
establish
toler
taa
link
herewith
presenc
ctl
suppress
tumor
microenviron
immunosuppress
statu
heavili
pretreat
patient
well
immunosuppress
statu
tumor
microenviron
argu
explor
viral
vaccin
earlier
diseas
stage
less
tumor
burden
first
virusbas
vaccin
approv
fda
evalu
earli
line
treatment
instead
last
line
becom
like
immunogen
situ
administ
viral
vector
act
doubleedg
sword
activ
dc
viral
vector
recognit
pathogenassoci
molecular
pattern
pattern
recognit
receptor
tlr
obviat
need
adjuv
moreov
type
ifndriven
antivir
immun
character
respons
therefor
strong
ctl
respons
gener
taa
deliv
viral
vector
sens
viral
antigen
howev
immunogen
entail
immun
also
build
viral
compon
antivir
immun
preclud
repeat
inject
viral
vaccin
hamper
prolong
transgen
express
neutral
vaccin
hinder
strength
taaspecif
cellular
immun
importantli
clinic
evalu
vector
like
pox
adenovir
vector
show
preexist
immun
respons
host
care
review
literatur
topic
preexist
immun
viral
vector
suggest
inde
hindranc
preexist
immun
impact
viral
vaccin
efficaci
depend
natur
immun
vector
essenc
viral
infect
elicit
robust
b
cell
memori
respons
reduc
antigen
deliveri
viral
vector
due
neutral
antibodi
moreov
preexist
antivir
respons
lead
rapid
vector
clearanc
reduc
exposur
heterolog
antigen
taa
immun
system
final
immun
respons
could
focu
strong
viral
antigen
ignor
coexpress
taa
via
process
epitop
domin
importantli
sever
approach
appli
avoid
downsid
preexist
vector
immun
use
vector
deriv
nonhuman
sourc
rare
serotyp
altern
approach
provid
regimen
two
differ
recombin
viral
vaccin
express
taa
use
consecut
one
also
alter
viral
surfac
epitop
envelop
capsid
protein
might
elicit
neutral
antibodi
inhibitori
effect
preexist
immun
also
avoid
mask
viral
vector
insid
dc
discuss
section
adenoviralbas
vaccin
besid
mucos
high
dose
vaccin
also
shown
overcom
preexist
immun
problem
recent
studi
show
inhibitor
celecoxib
prevent
gener
neutral
antibodi
vaccinia
allow
repeat
administr
without
lose
infect
preexist
immun
howev
issu
virusbas
vaccin
instanc
major
popul
never
contact
lentivirus
make
vector
deriv
attract
candid
vaccin
develop
therefor
may
surpris
lentivir
vaccin
clinic
evalu
hand
trial
show
improv
durabl
respons
sarcoma
patient
note
rout
administr
profoundli
affect
biodistribut
viral
vector
turn
influenc
therapi
efficaci
toxic
profil
exampl
intraven
inject
aav
via
tail
vein
trigger
celldepend
humor
respons
deliveri
via
portal
circul
lead
cellindepend
b
cell
respons
importantli
tissuespecif
deliveri
issu
nake
protein
nucleic
acidbas
vaccin
viral
vector
often
hold
natur
tropism
specif
cell
tissu
virusbas
vaccin
excel
vehicl
tissuespecif
deliveri
transgen
togeth
intrins
immunogen
exampl
adenovir
vector
scaveng
reticuloendotheli
system
system
inject
especi
kupffer
cell
liver
howev
upon
intranas
administr
encod
adenovir
vector
pulmonari
metastasi
murin
model
osteosarcoma
could
treat
without
put
risk
discuss
epitheli
tropism
hpvderiv
vector
could
endow
optim
featur
prophylact
therapeut
hpvrelat
cancer
vaccin
addit
viral
vector
extens
reengin
order
alter
tropism
transgen
express
extens
discuss
elsewher
target
viral
vector
dc
explor
mean
tighten
control
viral
vector
deliv
enhanc
safeti
efficaci
approach
adapt
lentivir
adenovir
vector
use
singl
domain
antibodi
socal
nanobodi
specif
bind
apc
albeit
dc
dc
macrophag
although
expect
approach
would
enhanc
vaccin
efficaci
avoid
present
nonprofession
apc
strategi
deliv
promis
part
explain
enhanc
antivir
type
ifn
respons
next
lack
stromal
cell
transduct
reduc
mhci
mediat
antigen
present
evergrow
field
cancer
antigen
target
identif
lead
knowledg
platform
develop
complet
tumor
erad
vaccin
far
howev
larg
clinic
trial
meet
expect
like
explain
inconsist
express
pattern
taa
within
heterogen
tumor
mass
well
vaccineinduc
tumor
evas
time
concept
neoantigen
harbor
highaffin
cell
recogniz
tumoruniqu
epitop
becom
indispens
next
gener
antitumor
viral
vaccin
far
mainli
oncolyt
viral
system
link
modul
spectrum
neoantigen
specif
ctl
subsequ
abrog
system
resist
checkpoint
inhibitor
immunotherapi
furthermor
adenovir
mva
vector
test
neoantigen
encod
vaccin
framework
human
immunodefici
viru
relat
diseas
specif
genet
algorithmbas
mosaic
method
develop
gener
artifici
protein
sequenc
could
increas
crossreact
vaccin
respons
divers
isol
mosaic
hiv
sequenc
deliv
via
adenoviru
mva
result
strong
protect
effect
subsequ
infect
nonhuman
primat
find
encourag
develop
cancer
neoantigen
encod
viral
vector
treatment
cancer
tumorderiv
dc
often
dysfunct
less
matur
low
sensit
tlr
activ
associ
hyperact
ideal
vaccin
therefor
consist
taa
togeth
adjuv
overcom
dc
anerg
state
field
nanovaccin
sever
combin
explor
deliveri
one
antigenadjuvantgenet
silenc
eg
small
interf
rna
exactli
viral
vector
could
especi
viral
vector
larg
genet
insert
capac
poxviru
baculoviru
could
use
purpos
furthermor
viral
vector
could
also
use
target
deliveri
protein
cell
interest
aka
protein
transfer
vector
ptv
therefor
research
strategi
exploit
advantag
trait
virus
eg
high
infect
adjuv
potenti
avoid
trait
develop
avoid
immun
respons
eg
decreas
translat
machineri
continu
final
also
make
sens
combin
dctarget
vaccin
purpos
elicit
antitumor
cell
respons
strategi
design
support
function
cell
tumor
microenviron
regard
immun
checkpoint
inhibitor
might
ideal
candid
drug
abl
releas
brake
cell
impos
inhibitori
receptor
nice
exemplifi
combin
adenovir
vector
encod
murin
breast
taa
intraperiton
inject
bifunct
fusion
protein
combin
shown
induc
activ
ctl
nk
cell
phenotyp
within
tumor
microenviron
previous
perform
therapi
experi
ovalbumin
ova
express
thymoma
model
combin
dctarget
lv
encod
ova
treatment
led
prolong
overal
surviv
compar
inject
lv
antibodi
alon
figur
moreov
result
protect
subsequ
challeng
lethal
dose
cell
suggest
dctarget
lv
promis
immunotherapeut
combin
cell
suppress
counteract
strategi
natur
finetun
virus
highli
effici
gene
transmitt
cellspecif
fashion
intrins
adjuvantlik
featur
henc
abund
rang
viral
vector
explor
tweak
substanti
develop
anticanc
vaccin
specif
featur
result
believ
matter
find
onefitsal
vector
appropri
combin
cancer
type
stage
issu
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
